The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1056
July 2, 1999
View Complete Issue         Table of Contents 2019 
Rofecoxib for Osteoarthritis and Pain
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Rofecoxib for Osteoarthritis and Pain
July 2, 1999 (Issue: 1056)
Rofecoxib, a selective COX-2 inhibitor, has been approved by the FDA for treatment of osteoarthritis, acute pain and menstrual pain.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Rofecoxib for Osteoarthritis and Pain
Article code: 1056a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.